^
CANCER:
Prostate Cancer
CD8 expression
|
Prostate Cancer
|
CD8 expression
|
Prostate Cancer
|
atezolizumab + enzalutamide Sensitive: B - Late Trials
Nature - 2 weeks
|
atezolizumab + enzalutamide Sensitive: B - Late Trials
Nature - 2 weeks
|
PD-L1 overexpression
|
Prostate Cancer
|
PD-L1 overexpression
|
Prostate Cancer
|
atezolizumab + enzalutamide Sensitive: B - Late Trials
Nature - 2 weeks
|
atezolizumab + enzalutamide Sensitive: B - Late Trials
Nature - 2 weeks
|
No biomarker
|
Prostate Cancer
|
No biomarker
|
Prostate Cancer
|
apalutamide Sensitive: A1 - Approval
|
apalutamide Sensitive: A1 - Approval
|
No biomarker
|
Prostate Cancer
|
No biomarker
|
Prostate Cancer
|
histrelin acetate Sensitive: A1 - Approval
|
histrelin acetate Sensitive: A1 - Approval
|
No biomarker
|
Prostate Cancer
|
No biomarker
|
Prostate Cancer
|
cabazitaxel Sensitive: A1 - Approval
|
cabazitaxel Sensitive: A1 - Approval
|
BRCA2 mutation
|
Prostate Cancer
|
BRCA2 mutation
|
Prostate Cancer
|
olaparib Sensitive: A1 - Approval
|
olaparib Sensitive: A1 - Approval
|
BRCA1 mutation
|
Prostate Cancer
|
BRCA1 mutation
|
Prostate Cancer
|
olaparib Sensitive: A1 - Approval
|
olaparib Sensitive: A1 - Approval
|
No biomarker
|
Prostate Cancer
|
No biomarker
|
Prostate Cancer
|
enzalutamide Sensitive: A1 - Approval
|
enzalutamide Sensitive: A1 - Approval
|
No biomarker
|
Prostate Cancer
|
No biomarker
|
Prostate Cancer
|
relugolix Sensitive: A1 - Approval
|
relugolix Sensitive: A1 - Approval
|
No biomarker
|
Prostate Cancer
|
No biomarker
|
Prostate Cancer
|
docetaxel + prednisone Sensitive: A1 - Approval
|
docetaxel + prednisone Sensitive: A1 - Approval
|
No biomarker
|
Prostate Cancer
|
No biomarker
|
Prostate Cancer
|
abiraterone acetate Sensitive: A1 - Approval
|
abiraterone acetate Sensitive: A1 - Approval
|
No biomarker
|
Prostate Cancer
|
No biomarker
|
Prostate Cancer
|
degarelix Sensitive: A1 - Approval
|
degarelix Sensitive: A1 - Approval
|
ATM mutation
|
Prostate Cancer
|
ATM mutation
|
Prostate Cancer
|
olaparib Sensitive: A1 - Approval
|
olaparib Sensitive: A1 - Approval
|
No biomarker
|
Prostate Cancer
|
No biomarker
|
Prostate Cancer
|
darolutamide Sensitive: A1 - Approval
|
darolutamide Sensitive: A1 - Approval
|
BRCA1 mutation
|
Prostate Cancer
|
BRCA1 mutation
|
Prostate Cancer
|
rucaparib Sensitive: A1 - Approval
|
rucaparib Sensitive: A1 - Approval
|
BRCA2 mutation
|
Prostate Cancer
|
BRCA2 mutation
|
Prostate Cancer
|
rucaparib Sensitive: A1 - Approval
|
rucaparib Sensitive: A1 - Approval
|
HRD
|
Prostate Cancer
|
HRD
|
Prostate Cancer
|
olaparib Sensitive: A1 - Approval
|
olaparib Sensitive: A1 - Approval
|
No biomarker
|
Prostate Cancer
|
No biomarker
|
Prostate Cancer
|
zoledronic acid Sensitive: A1 - Approval
|
zoledronic acid Sensitive: A1 - Approval
|
No biomarker
|
Prostate Cancer
|
No biomarker
|
Prostate Cancer
|
leuprolide mesylate injectable suspension Sensitive: A1 - Approval
|
leuprolide mesylate injectable suspension Sensitive: A1 - Approval
|
MSI-H/dMMR
|
Prostate Cancer
|
MSI-H/dMMR
|
Prostate Cancer
|
pembrolizumab Sensitive: A2 - Guideline
|
pembrolizumab Sensitive: A2 - Guideline
|
No biomarker
|
Prostate Cancer
|
No biomarker
|
Prostate Cancer
|
mitoxantrone Sensitive: A2 - Guideline
|
mitoxantrone Sensitive: A2 - Guideline
|
No biomarker
|
Prostate Cancer
|
No biomarker
|
Prostate Cancer
|
etoposide IV Sensitive: A2 - Guideline
|
etoposide IV Sensitive: A2 - Guideline
|
No biomarker
|
Prostate Cancer
|
No biomarker
|
Prostate Cancer
|
atezolizumab Sensitive: A2 - Guideline
|
atezolizumab Sensitive: A2 - Guideline
|
No biomarker
|
Prostate Cancer
|
No biomarker
|
Prostate Cancer
|
docetaxel Sensitive: A2 - Guideline
|
docetaxel Sensitive: A2 - Guideline
|
CDK12 mutation
|
Prostate Cancer
|
CDK12 mutation
|
Prostate Cancer
|
olaparib Sensitive: A2 - Guideline
|
olaparib Sensitive: A2 - Guideline
|
PALB2 mutation
|
Prostate Cancer
|
PALB2 mutation
|
Prostate Cancer
|
olaparib Sensitive: A2 - Guideline
|
olaparib Sensitive: A2 - Guideline
|
CHEK2 mutation
|
Prostate Cancer
|
CHEK2 mutation
|
Prostate Cancer
|
olaparib Sensitive: A2 - Guideline
|
olaparib Sensitive: A2 - Guideline
|
CHEK1 mutation
|
Prostate Cancer
|
CHEK1 mutation
|
Prostate Cancer
|
olaparib Sensitive: A2 - Guideline
|
olaparib Sensitive: A2 - Guideline
|
AR splice variant 7
|
Prostate Cancer
|
AR splice variant 7
|
Prostate Cancer
|
abiraterone acetate Resistant: A2 - Guideline
|
abiraterone acetate Resistant: A2 - Guideline
|
AR splice variant 7
|
Prostate Cancer
|
AR splice variant 7
|
Prostate Cancer
|
enzalutamide Resistant: A2 - Guideline
|
enzalutamide Resistant: A2 - Guideline
|
RAD51B mutation
|
Prostate Cancer
|
RAD51B mutation
|
Prostate Cancer
|
olaparib Sensitive: A2 - Guideline
|
olaparib Sensitive: A2 - Guideline
|
RAD51C mutation
|
Prostate Cancer
|
RAD51C mutation
|
Prostate Cancer
|
olaparib Sensitive: A2 - Guideline
|
olaparib Sensitive: A2 - Guideline
|
RAD51D mutation
|
Prostate Cancer
|
RAD51D mutation
|
Prostate Cancer
|
olaparib Sensitive: A2 - Guideline
|
olaparib Sensitive: A2 - Guideline
|
RAD54L mutation
|
Prostate Cancer
|
RAD54L mutation
|
Prostate Cancer
|
olaparib Sensitive: A2 - Guideline
|
olaparib Sensitive: A2 - Guideline
|
FANCL mutation
|
Prostate Cancer
|
FANCL mutation
|
Prostate Cancer
|
olaparib Sensitive: A2 - Guideline
|
olaparib Sensitive: A2 - Guideline
|
BRIP1 mutation
|
Prostate Cancer
|
BRIP1 mutation
|
Prostate Cancer
|
olaparib Sensitive: A2 - Guideline
|
olaparib Sensitive: A2 - Guideline
|
BARD1 mutation
|
Prostate Cancer
|
BARD1 mutation
|
Prostate Cancer
|
olaparib Sensitive: A2 - Guideline
|
olaparib Sensitive: A2 - Guideline
|
PPP2R2A mutation
|
Prostate Cancer
|
PPP2R2A mutation
|
Prostate Cancer
|
olaparib Resistant: A2 - Guideline
|
olaparib Resistant: A2 - Guideline
|
No biomarker
|
Prostate Cancer
|
No biomarker
|
Prostate Cancer
|
sipuleucel-T Sensitive: A2 - Guideline
|
sipuleucel-T Sensitive: A2 - Guideline
|
No biomarker
|
Prostate Cancer
|
No biomarker
|
Prostate Cancer
|
histrelin acetate + nilutamide Sensitive: A2 - Guideline
|
histrelin acetate + nilutamide Sensitive: A2 - Guideline
|
No biomarker
|
Prostate Cancer
|
No biomarker
|
Prostate Cancer
|
bicalutamide + goserelin acetate Sensitive: A2 - Guideline
|
bicalutamide + goserelin acetate Sensitive: A2 - Guideline
|
No biomarker
|
Prostate Cancer
|
No biomarker
|
Prostate Cancer
|
goserelin acetate + flutamide Sensitive: A2 - Guideline
|
goserelin acetate + flutamide Sensitive: A2 - Guideline
|
No biomarker
|
Prostate Cancer
|
No biomarker
|
Prostate Cancer
|
goserelin acetate + nilutamide Sensitive: A2 - Guideline
|
goserelin acetate + nilutamide Sensitive: A2 - Guideline
|
No biomarker
|
Prostate Cancer
|
No biomarker
|
Prostate Cancer
|
triptorelin Sensitive: A2 - Guideline
|
triptorelin Sensitive: A2 - Guideline
|
No biomarker
|
Prostate Cancer
|
No biomarker
|
Prostate Cancer
|
leuprolide acetate Sensitive: A2 - Guideline
|
leuprolide acetate Sensitive: A2 - Guideline
|
No biomarker
|
Prostate Cancer
|
No biomarker
|
Prostate Cancer
|
goserelin acetate Sensitive: A2 - Guideline
|
goserelin acetate Sensitive: A2 - Guideline
|
No biomarker
|
Prostate Cancer
|
No biomarker
|
Prostate Cancer
|
abiraterone acetate + degarelix Sensitive: A2 - Guideline
|
abiraterone acetate + degarelix Sensitive: A2 - Guideline
|
No biomarker
|
Prostate Cancer
|
No biomarker
|
Prostate Cancer
|
abiraterone acetate + triptorelin Sensitive: A2 - Guideline
|
abiraterone acetate + triptorelin Sensitive: A2 - Guideline
|
No biomarker
|
Prostate Cancer
|
No biomarker
|
Prostate Cancer
|
abiraterone acetate + leuprolide acetate Sensitive: A2 - Guideline
|
abiraterone acetate + leuprolide acetate Sensitive: A2 - Guideline
|
No biomarker
|
Prostate Cancer
|
No biomarker
|
Prostate Cancer
|
abiraterone acetate + histrelin acetate Sensitive: A2 - Guideline
|
abiraterone acetate + histrelin acetate Sensitive: A2 - Guideline
|
No biomarker
|
Prostate Cancer
|
No biomarker
|
Prostate Cancer
|
abiraterone acetate + goserelin acetate Sensitive: A2 - Guideline
|
abiraterone acetate + goserelin acetate Sensitive: A2 - Guideline
|
No biomarker
|
Prostate Cancer
|
No biomarker
|
Prostate Cancer
|
bicalutamide + triptorelin Sensitive: A2 - Guideline
|
bicalutamide + triptorelin Sensitive: A2 - Guideline
|
No biomarker
|
Prostate Cancer
|
No biomarker
|
Prostate Cancer
|
triptorelin + flutamide Sensitive: A2 - Guideline
|
triptorelin + flutamide Sensitive: A2 - Guideline
|
No biomarker
|
Prostate Cancer
|
No biomarker
|
Prostate Cancer
|
triptorelin + nilutamide Sensitive: A2 - Guideline
|
triptorelin + nilutamide Sensitive: A2 - Guideline
|
No biomarker
|
Prostate Cancer
|
No biomarker
|
Prostate Cancer
|
leuprolide acetate + bicalutamide Sensitive: A2 - Guideline
|
leuprolide acetate + bicalutamide Sensitive: A2 - Guideline
|
No biomarker
|
Prostate Cancer
|
No biomarker
|
Prostate Cancer
|
leuprolide acetate + flutamide Sensitive: A2 - Guideline
|
leuprolide acetate + flutamide Sensitive: A2 - Guideline
|
No biomarker
|
Prostate Cancer
|
No biomarker
|
Prostate Cancer
|
leuprolide acetate + nilutamide Sensitive: A2 - Guideline
|
leuprolide acetate + nilutamide Sensitive: A2 - Guideline
|
No biomarker
|
Prostate Cancer
|
No biomarker
|
Prostate Cancer
|
bicalutamide + histrelin acetate Sensitive: A2 - Guideline
|
bicalutamide + histrelin acetate Sensitive: A2 - Guideline
|
No biomarker
|
Prostate Cancer
|
No biomarker
|
Prostate Cancer
|
histrelin acetate + flutamide Sensitive: A2 - Guideline
|
histrelin acetate + flutamide Sensitive: A2 - Guideline
|
No biomarker
|
Prostate Cancer
|
No biomarker
|
Prostate Cancer
|
carboplatin + docetaxel Sensitive: A2 - Guideline
|
carboplatin + docetaxel Sensitive: A2 - Guideline
|
No biomarker
|
Prostate Cancer
|
No biomarker
|
Prostate Cancer
|
carboplatin + etoposide oral Sensitive: A2 - Guideline
|
carboplatin + etoposide oral Sensitive: A2 - Guideline
|
No biomarker
|
Prostate Cancer
|
No biomarker
|
Prostate Cancer
|
cisplatin + etoposide oral Sensitive: A2 - Guideline
|
cisplatin + etoposide oral Sensitive: A2 - Guideline
|
TMB-H
|
Prostate Cancer
|
TMB-H
|
Prostate Cancer
|
pembrolizumab Sensitive: A2 - Guideline
|
pembrolizumab Sensitive: A2 - Guideline
|
No biomarker
|
Prostate Cancer
|
No biomarker
|
Prostate Cancer
|
carboplatin + cabazitaxel Sensitive: A2 - Guideline
|
carboplatin + cabazitaxel Sensitive: A2 - Guideline
|
AR amplification
|
Prostate Cancer
|
AR amplification
|
Prostate Cancer
|
enzalutamide Resistant: B - Late Trials
|
enzalutamide Resistant: B - Late Trials
|
BRCA1 mutation
|
Prostate Cancer
|
BRCA1 mutation
|
Prostate Cancer
|
niraparib Sensitive: B - Late Trials
|
niraparib Sensitive: B - Late Trials
|
BRCA2 mutation
|
Prostate Cancer
|
BRCA2 mutation
|
Prostate Cancer
|
niraparib Sensitive: B - Late Trials
|
niraparib Sensitive: B - Late Trials
|
No biomarker
|
Prostate Cancer
|
No biomarker
|
Prostate Cancer
|
CYP17A1 inhibitor Sensitive: B - Late Trials
|
CYP17A1 inhibitor Sensitive: B - Late Trials
|
No biomarker
|
Prostate Cancer
|
No biomarker
|
Prostate Cancer
|
RV001 Sensitive: B - Late Trials
|
RV001 Sensitive: B - Late Trials
|
PTEN mutation
|
Prostate Cancer
|
PTEN mutation
|
Prostate Cancer
|
bicalutamide Sensitive: B - Late Trials
|
bicalutamide Sensitive: B - Late Trials
|
PTEN loss
|
Prostate Cancer
|
PTEN loss
|
Prostate Cancer
|
RG7440 + AST-2970 + prednisolone Sensitive: B - Late Trials
|
RG7440 + AST-2970 + prednisolone Sensitive: B - Late Trials
|
No biomarker
|
Prostate Cancer
|
No biomarker
|
Prostate Cancer
|
EPI-7386 Sensitive: B - Late Trials
|
EPI-7386 Sensitive: B - Late Trials
|
No biomarker
|
Prostate Cancer
|
No biomarker
|
Prostate Cancer
|
ipilimumab Sensitive: B - Late Trials
|
ipilimumab Sensitive: B - Late Trials
|
AR amplification
|
Prostate Cancer
|
AR amplification
|
Prostate Cancer
|
AST-2970 Resistant: B - Late Trials
|
AST-2970 Resistant: B - Late Trials
|
TP53 deletion
|
Prostate Cancer
|
TP53 deletion
|
Prostate Cancer
|
abiraterone acetate Resistant: B - Late Trials
|
abiraterone acetate Resistant: B - Late Trials
|
TP53 deletion
|
Prostate Cancer
|
TP53 deletion
|
Prostate Cancer
|
enzalutamide Resistant: B - Late Trials
|
enzalutamide Resistant: B - Late Trials
|
RB1 deletion
|
Prostate Cancer
|
RB1 deletion
|
Prostate Cancer
|
abiraterone acetate Resistant: B - Late Trials
|
abiraterone acetate Resistant: B - Late Trials
|
RB1 deletion
|
Prostate Cancer
|
RB1 deletion
|
Prostate Cancer
|
enzalutamide Resistant: B - Late Trials
|
enzalutamide Resistant: B - Late Trials
|
BRCA2 deletion
|
Prostate Cancer
|
BRCA2 deletion
|
Prostate Cancer
|
enzalutamide Sensitive: B - Late Trials
|
enzalutamide Sensitive: B - Late Trials
|
BRCA2 deletion
|
Prostate Cancer
|
BRCA2 deletion
|
Prostate Cancer
|
abiraterone acetate Sensitive: B - Late Trials
|
abiraterone acetate Sensitive: B - Late Trials
|
BRCA1 positive
|
Prostate Cancer
|
BRCA1 positive
|
Prostate Cancer
|
olaparib Sensitive: B - Late Trials
|
olaparib Sensitive: B - Late Trials
|
BRCA2 positive
|
Prostate Cancer
|
BRCA2 positive
|
Prostate Cancer
|
olaparib Sensitive: B - Late Trials
|
olaparib Sensitive: B - Late Trials
|
ATM positive
|
Prostate Cancer
|
ATM positive
|
Prostate Cancer
|
olaparib Sensitive: B - Late Trials
|
olaparib Sensitive: B - Late Trials
|
PTEN negative
|
Prostate Cancer
|
PTEN negative
|
Prostate Cancer
|
RG7440 Sensitive: B - Late Trials
|
RG7440 Sensitive: B - Late Trials
|
FOLH1 positive
|
Prostate Cancer
|
FOLH1 positive
|
Prostate Cancer
|
177 Lu PSMA-617 Sensitive: B - Late Trials
|
177 Lu PSMA-617 Sensitive: B - Late Trials
|
No biomarker
|
Prostate Cancer
|
No biomarker
|
Prostate Cancer
|
177 Lu PSMA-617 Sensitive: B - Late Trials
|
177 Lu PSMA-617 Sensitive: B - Late Trials
|
PTEN deletion
|
Prostate Cancer
|
PTEN deletion
|
Prostate Cancer
|
RG7440 Sensitive: B - Late Trials
|
RG7440 Sensitive: B - Late Trials
|
No biomarker
|
Prostate Cancer
|
No biomarker
|
Prostate Cancer
|
olaparib Sensitive: B - Late Trials
|
olaparib Sensitive: B - Late Trials
|
PD-L1 expression
|
Prostate Cancer
|
PD-L1 expression
|
Prostate Cancer
|
pembrolizumab Sensitive: C1 - Off-label
|
pembrolizumab Sensitive: C1 - Off-label
|
PD-L1 expression
|
Prostate Cancer
|
PD-L1 expression
|
Prostate Cancer
|
durvalumab Sensitive: C1 - Off-label
|
durvalumab Sensitive: C1 - Off-label
|
MSI-H/dMMR
|
Prostate Cancer
|
MSI-H/dMMR
|
Prostate Cancer
|
nivolumab Sensitive: C1 - Off-label
|
nivolumab Sensitive: C1 - Off-label
|
BRCA2 mutation
|
Prostate Cancer
|
BRCA2 mutation
|
Prostate Cancer
|
talazoparib Sensitive: C1 - Off-label
|
talazoparib Sensitive: C1 - Off-label
|
PD-L1 expression
|
Prostate Cancer
|
PD-L1 expression
|
Prostate Cancer
|
nivolumab + ipilimumab Sensitive: C1 - Off-label
|
nivolumab + ipilimumab Sensitive: C1 - Off-label
|
BRCA1 mutation
|
Prostate Cancer
|
BRCA1 mutation
|
Prostate Cancer
|
talazoparib Sensitive: C1 - Off-label
|
talazoparib Sensitive: C1 - Off-label
|
